AUA 2018: Inferior Vena Cava Level II Tumor Thrombectomy: Which is Best: Robot or Open?

San Francisco, CA ( In this plenary session, Drs. Leibovich and Gill once again debated the best approach to a Level II Tumor Thrombus.  Mark Soloway introduced the topic. He made some important baseline points:  This is one of the most complex procedures we do in Urology – and morbidity can be high in inexperienced hands. The key to success is preparation, experience, exposure and vascular control. He provided guidance regarding liver mobilization for level II and III thrombi and emphasized the need for a multi-disciplinary team. 

AUA 2017: Best Abstract – Are the current follow-up guidelines after treatment for organ confined renal cancer sufficient?

Boston, MA ( This study raises a provocative question – Are the current followup guidelines adequate after partial nephrectomy. The authors retrospectively queried 880 patients undergoing partial nephrectomy for RCC less than pT2b.

AUA 2017: Best Abstract – Liquid biopsy for renal cell carcinoma

Boston, MA ( In this presentation, Dr. Al-Qassab described the concept of using circulating tumor DNA (ctDNA) as a novel biomarker for the diagnosis and surveillance of renal cancer. The advantage of using ctDNA is due to its ease of collection from peripheral blood, and can be accessed in a relatively non-invasive manner.

AUA 2017: A molecular scoring algorithm to predict survival in metastatic renal cell carcinoma

Boston, MA ( There has been rapid adoption of using molecular signatures to classify clinical outcomes by urologic researchers. Previously described prognostic models using clinicopathologic features for metastatic RCC yield imperfect results, with an average C index of 0.66. In this study from the Mayo Clinic, the gene expression profile of metastatic RCC was examined, and a score for characterizing the clinical course was described.

AUA 2017: Thromboembolic events during treatment for renal cell carcinoma: must we prevent?

Boston, MA ( In this retrospective analysis over a fourteen year period, the authors describe the incidences of symptomatic venous thromboembolism (VTE) events following surgery for renal cell carcinoma. This is a relevant topic as CMS has emphasized the importance of VTE prophylaxis in the perioperative setting and in total, approximately $10 billion are spent on prevention and treatment of VTE per year.

AUA 2017: Can looks deceive? Not all clinically “cystic” renal masses harbor indolent biology

Boston, MA ( In this study by investigators from Fox Chase Cancer Center, the surgical pathology from cystic renal masses were examined. Traditionally cystic renal cell carcinomas are thought to be clinically indolent.

AUA 2017: Differential gene expression in patients with indolent versus aggressive chromophobe renal cell carcinoma: An analysis of the cancer genome atlas database

Boston, MA ( This re-analysis of the TCGA database stratified patients by their overall survival after being diagnosed with chromophobe RCC. In the analysis, 200 overexpressed genes were identified in patients who deceased after diagnosis. The study further identified that the majority of the overexpressed genes were related to cell replication and cell cycle (56%), followed by DNA repair (9%), and intracellular metabolism (7.5%).